Drug Approval
Name: Ztalmy
Indications: To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder
Active Ingredient: ganaxolone
Company: Marinus Pharmaceuticals, Inc.
Approval Date: 3/18/2022
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf